Jorge J. Castillo, MD, discusses preliminary data from a phase 2 study of acalabrutinib plus rituximab in patients with IgM symptomatic anti-MAG peripheral neuropathy.
Jorge J. Castillo, MD, discusses the ongoing investigation into potential treatment options for patients with Waldenström macroglobulinemia, including iopofosine I-131.
Data from four pivotal trials continue to build evidence base for BRUKINSA (zanubrutinib) in B-cell malignancies Pipeline showing promise with early data for BGB-11417, a BCL-2 inhibitor, as monotherapy